Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB003 phase 2 study in corticosteroid-inadequately controlled asthma
2012-001791-11Phase 2Completed
- Sponsor
- KaloBios Pharmaceuticals
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing KB003 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in percent predicted FEV1 over 24 weeks. Started Jun 2012; status: completed.
02
Drugs
lenzilumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-001791-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001791-11.